Abiopharma

POLARYX THERAPEUTICS, INC. (PLYX)

Symbol	PLYX
Name	POLARYX THERAPEUTICS, INC.
Sector	UNDEFINED
Region	North America
Industry	Pharmaceutical Preparations
Address	SOUTH TOWER, 140 E RIDGEWOOD AVENUE,SUITE 415, PARAMUS, New Jersey, 07652, United States
Telephone	+1 201 940-7236
Fax	—
Email	—
Website	www.polaryx.com
Incorporation	UNDEFINED
Incorporated On	—
Employees	—
Fiscal Year	—
Public Since	—
Exchanges	NASDAQ
Auditor	—
Audit Status	NOT PROVIDED
Reporting Status	—
CIK	0002075320
Description	Polaryx Therapeutics is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders ("LSDs"). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs. Our most advanced product candidate, PLX-200, targets several LSDs and we intend to launch a Phase 2 proof-of-concept basket trial which may enhance PLX-200s potential to become the standard of care across multiple LSDs. Additional info from NASDAQ: Polaryx Therapeutics is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders ("LSDs"). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs. Our most advanced product candidate, PLX-200, targets several LSDs and we intend to launch a Phase 2 proof-of-concept basket trial which may enhance PLX-200s potential to become the standard of care across multiple LSDs.

2026-07-28 18:04

New Form ARS - Polaryx Therapeutics, Inc. Filed: 2026-07-28 AccNo: 0001213900-26-082353 Size: 5 MB

2026-07-28 18:00

New Form DEF 14A - Polaryx Therapeutics, Inc. Filed: 2026-07-28 AccNo: 0001213900-26-082339 Size: 6 MB

2026-07-21 20:30

(99% Neutral) POLARYX THERAPEUTICS, INC. (PLYX) Announces Executive Departure

2026-07-17 12:00

(99% Neutral) POLARYX THERAPEUTICS, INC. (PLYX) Files Form 8-K

2026-05-29 00:00

Director Yang Alex Keun Mo 🟢 acquired 88.5K shares of Polaryx Therapeutics, Inc. (PLYX) at $4.07 Transaction Date: May 27, 2026 | Filing ID: 062322

2026-05-28 20:31

(75% Positive) POLARYX THERAPEUTICS, INC. (PLYX) Provides Update on resulting for proceeds of $10 million

2026-05-28 12:30

Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial

2026-05-14 13:15

Polaryx Therapeutics Receives GHP Magazine’s Healthcare & Pharmaceuticals Awards

2026-04-21 12:30

Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial

2026-04-15 13:15

Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care